atopic dermatitis

Funding
Biotech

Enveda reaps $311M round to help become ‘household name’

The series E round positions the nature-derived drug discovery company to pursue its goal of becoming a household name over the next decade.
Nick Paul Taylor Sep 23, 2026 9:47am
t-rex Tyrannosaurus dinosaur reptile monster

Retension, Lilly-backed TRex both plan to join IPO stampede

Sep 21, 2026 4:29am
public companies

Atopic dermatitis biotech heads to Nasdaq via reverse merger

Sep 17, 2026 7:40am
Goal disorientation and lack of vision

Evommune gives up on dermatitis drug after another ph. 2 fail

Sep 9, 2026 4:04am
Saplings growing with increasing denominations of money wrapped around them

Regeneron backs $75M series A for antibody upstart Infinimmune

Aug 11, 2026 8:00am
Sanofi

Sanofi won't seek approval for eczema drug from Kymab buyout

Jul 24, 2026 5:13am